Discovery and Validation of a Novel Metastasis-Related lncRNA Prognostic Signature for Colorectal Cancer

Abstract

Background: Cancer metastasis-related chemoresistance and tumour progression are the leading causes of death among CRC patients. Therefore, it is urgent to identify reliable novel biomarkers for predicting the metastasis of CRC.Methods: The gene expression and corresponding clinical data of CRC patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Univariate and multivariate analyses were performed to identify prognostic metastasis-related lncRNAs. Nomograms were constructed, and the predictive accuracy of the nomogram model was assessed by ROC curve analysis. Then, the R package “pRRophetic” was used to predict chemotherapeutic response in CRC patients. In addition, the CIBERSORT database was introduced to evaluate tumour infiltrating immune cells between the high—and low-risk groups. The potential roles of SNHG7 and ZEB1-AS1 in CRC cell lines were further confirmed by in vitro experiments.Results: An 8-lncRNA (LINC00261, RP1-170O19.17, CAPN10-AS1, SNHG7, ZEB1-AS1, U47924.27, NIFK-AS1, and LINC00925) signature was constructed for CRC prognosis prediction, which stratified patients into two risk groups. Kaplan-Meier analysis revealed that patients in the higher-risk group had a lower survival probability than those in the lower-risk group [p < 0.001 (TCGA); P = 0.044 (GSE39582); and P = 0.0078 (GSE29621)] The AUCs of 1-, 3-, and 5-year survival were 0.678, 0.669, and 0.72 in TCGA; 0.58, 0.55, and 0.56 in GSE39582; and 0.75, 0.54, and 0.56 in GSE29621, respectively. In addition, the risk score was an independent risk factor for CRC patients. Nomograms were constructed, and the predictive accuracy was assessed by ROC curve analysis. This signature could effectively predict the immune status and chemotherapy response in CRC patients. Moreover, SNHG7 and ZEB1-AS1 depletion significantly suppressed the colony formation, migration, and invasion of CRC cells in vitro.Conclusion: We constructed a signature that could predict the metastasis of CRC and provide certain theoretical guidance for novel therapeutic approaches for CRC.

Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs

“…NIFK-AS1 was found to potentially participate in dilated cardiomyopathy (DCM) through ceRNA [ 36 ]. Tang et al found NIFK-AS has been included in the prognostic signature to predict the prognosis of colorectal cancer(CRC) patients [ 37 ]. All these results indicate that NIFK-AS1 is a novel therapeutic target.…”

LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation

“…The observation of heterogeneity in the expression of MIR200CHG is highly consistent with our findings in GC. In addition, MIR200CHG has been reported to be a prognostic biomarker by serving as a protective factor 48 – 50 or risk factor 51 in bladder urothelial carcinoma 48 , lung adenocarcinoma 49 , melanoma 50 , and colorectal cancer 51 based on in silico analysis of public datasets. Therefore, the function of MIR200CHG may be cancer tissue-dependent, cancer subtype-dependent and impacted by other factors such as subcellular localization.…”

Significance of platelet adhesion-related genes in colon cancer based on non-negative matrix factorization-based clustering algorithm

“…Four lncRNAs (ARRDC1-AS1, OIP5-AS1, BOLA3-AS1, and NIFK-AS1) were mentioned in previous COAD studies. 59 – 62 Collectively, these factors may lead to the further exploration of COAD progression and can be investigated as biomarkers and therapeutic targets for COAD.…”